Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Aug;9(8):2397-2403.
doi: 10.21037/jtd.2017.07.02.

The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR

Affiliations

The detectability of the pretreatment EGFR T790M mutations in lung adenocarcinoma using CAST-PCR and digital PCR

Tsutomu Tatematsu et al. J Thorac Dis. 2017 Aug.

Abstract

Background: A gatekeeper T790M mutation is thought to cause resistance to epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment. The detection of a 2nd mutation is important for planning the next therapy when patients acquire resistance to the first line EGFR-TKI.

Methods: We used a competitive allele-specific polymerase chain reaction (CAST-PCR) to analyze the incidence and clinical significance of T790M mutations in 153 lung adenocarcinomas with EGFR-activating mutations. To increase the sensitivity and specificity of the detection of T790M mutations, we subjected 20 of the 153 cases to a digital PCR. The genomic DNAs were extracted from frozen, surgically resected tumor tissue specimens.

Results: The CAST-PCR detected T790M mutations in 45 (29.4%) of the 153 cases. The analytical sensitivity in the detection T790M mutations was 0.13-2.65% (average 0.27%, median 0.20%). In contrast, the digital PCR, detected T790M mutations in 8 (40%) out of 20 cases.

Conclusions: Our study shows that the pretreatment incidence of T790M mutation was less than that reported in previous studies. In order to clinically use pretreatment EGFR T790M mutation identification method, we should clarify the adequate methods and tissue preserved status.

Keywords: CAST-PCR; EGFR mutation; Non-small cell lung cancer (NSCLC); T790M mutation; digital PCR.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Overall survival (A) and recurrence-free survival (B) stratified according to the T790M mutation status.
Figure 2
Figure 2
The T790M mutation status was investigated using a digital PCR. Blue plot (T790-positive): high FAM fluorescence intensity was only observed in T790M mutations. Green plot (T790M-negative): the T790M mutation + wild-type showed a high FAM fluorescence intensity. Red plot (T790M-negative): only the wild-type showed a high FAM fluorescence intensity. PCR, polymerase chain reaction.
Figure 3
Figure 3
Four cases in which a digital PCR was performed to detect T790M mutations. Blue plot (T790-positive): High FAM fluorescence intensity was only observed in T790M mutations. Green plot (T790M-negative): the T790M mutation + wild-type showed a high FAM fluorescence intensity. Red plot (T790M-negative): only the wild-type showed a high FAM fluorescence intensity. A (case 3) and B (case 13) show T790M mutation-negative cases. C (case 14) and D (case 15) show T790M mutation-positive cases. PCR, polymerase chain reaction.

Similar articles

Cited by

References

    1. Lewis DR, Check DP, Caporaso NE, et al. US Lung Cancer Trends by Histologic Type. Cancer 2014;120:2883-92. 10.1002/cncr.28749 - DOI - PMC - PubMed
    1. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500. 10.1126/science.1099314 - DOI - PubMed
    1. Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer 2006;118:180-4. 10.1002/ijc.21301 - DOI - PubMed
    1. Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011;29:2866-74. 10.1200/JCO.2010.33.4235 - DOI - PubMed
    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed